GLP-1 Price Explained: Insurance and Savings

This guide belongs to the PlexusDx Education Hub, where we translate GLP-1 science, weight-management protocols, and the genetics of metabolism into plain language you can actually use.

GLP-1 price is one of the most-searched questions in this space, and the answer is layered. What you pay depends on insurance, the indication on your prescription, savings-card eligibility, pharmacy pricing, and whether a compounded route is available. This guide unpacks each of those factors, all as of April 2026 and reported as published.

What the list number really is

GLP-1 list price varies by brand per month at U.S. list price as of April 2026. It is the figure before insurance, rebates, savings cards, and pharmacy negotiation, which is why it rarely matches what an insured patient pays. Treat it as the starting line, not the finish, and expect your real cost to depend on the variables below.

Insurance and prior authorization

Commercial coverage hinges on whether the prescription is written for an FDA-approved indication and on the plan's formulary and prior authorization rules. Many commercial plans cover GLP-1 agonists for type 2 diabetes, while chronic weight management coverage varies more widely, often behind BMI-based prior authorization, and some plans exclude weight indications entirely. Medicare does not cover FDA-approved weight-management drugs for weight alone as of April 2026, though cardiovascular-indication coverage exists for some products.

Savings cards and their exclusions

The manufacturer savings-card programs can substantially cut monthly cost for eligible commercially insured patients, but eligibility typically excludes Medicare, Medicaid, TRICARE, and other government insurance. Cards carry monthly and annual caps, and terms change, so verify on the manufacturer site at the time of fill. Independent platforms such as GoodRx and SingleCare separately publish coupon prices that vary by pharmacy.

The 2024 to 2025 compounding shift

During the FDA-declared shortages of semaglutide and tirzepatide, licensed 503A compounding pharmacies legally produced compounded formulations of these molecules. The FDA resolved the semaglutide shortage in late 2024 and the tirzepatide shortage in early 2025, narrowing but not eliminating legitimate compounding activity. Compounded products remain available through licensed pathways where clinically justified, and they are not identical to brand products.

Realistic out-of-pocket scenarios

With commercial insurance that covers the indication and a savings card applied, eligible patients may pay as little as $25 per month depending on plan terms and caps. Without coverage for the indication, cash-pay costs move closer to list minus any coupon. PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols, with per-protocol pricing published on each product page such as Semaglutide Injection and Tirzepatide Injection.

Why quoted prices vary so widely online

Search results for GLP-1 pricing can look contradictory because each figure reflects a different vantage point in the coverage stack. A number pulled from a manufacturer list page, an amount after a commercial plan plus savings card, a Medicare patient locked out of both, and a compounded-protocol figure are four legitimate but non-comparable answers. That is why a single quoted price rarely predicts your own. The productive move is to identify which situation matches yours, then verify the current terms at that layer, whether that means calling your plan about prior authorization, checking the manufacturer card's caps and exclusions, or reading the published per-protocol pricing for a compounded option. The number that matters is the one built from your specific coverage, not the lowest figure floating online.

The genetic layer sitting underneath every GLP-1 decision

Variants in FTO, GLP1R, and MC4R shape appetite, receptor signaling, and baseline energy balance. None of these variants forecast how a particular medication will behave in your body, and the Precision Peptide Genetic Test is not a pharmacogenomic tool. What it does is map trait-level tendencies across your metabolism: this single 503A-appropriate readout covers 14 pathways, 49 peptides, 150+ genetic insights, giving you and your clinician a shared picture of the terrain before any protocol begins. Anchoring the spend to your biology beats chasing the lowest sticker in isolation.

Frequently Asked Questions

How much does a GLP-1 cost per month?

List price varies by brand per month at U.S. list price as of April 2026. Insurance, savings cards, and pharmacy pricing can substantially change what you pay at the counter, so the list figure is only a reference point. Confirm the current price with the pharmacy before you fill.

Does insurance cover GLP-1 medications?

It depends on the plan, the formulary, the FDA indication on the prescription, and prior authorization. Many commercial plans cover these agonists for type 2 diabetes, while weight-management coverage is more variable. Medicare does not cover weight-management indications for weight alone as of April 2026.

Can I really pay as little as $25 a month?

Some eligible commercially insured patients can, when the plan covers the indication and a manufacturer savings card applies, subject to that card's monthly and annual caps. Government-insurance patients are usually excluded from these cards, so the low figure is not universal. Verify your specific terms at the time of fill.

Are lower-cost compounded options available?

Yes. Licensed 503A pharmacies produce compounded semaglutide and tirzepatide at separate price points from brand products. These are legally and factually different, not generics. PlexusDx offers both through its Weight Management Protocols, with published per-protocol pricing on each product page.